Genomics

10x Genomics Q3 Revenues Grow 67 Percent | GenomeWeb | 11/8/2019

NEW YORK – 10x Genomics reported a 67 percent increase in third quarter revenues after Thursday. For the three months ended Sept. 30, 10x reported $61.2 million in revenues, up from $36.6 million during the year-ago period and beating the average Wall Street estimate of $54.9 million …

A Roadmap and Wish List for Synthetic Genomics | 11/8/2019

… CAR-T medicines, genetically engineered crops, and more. One sector still in its infancy is synthetic genomics, where instead of one protein or gene, entire genomes are designed, synthesized, and implemented. To make synthetic genomics bloom, it needs new innovations and support, concludes a new report by a consortium of scientists from academia and industry, published recently in Science . Nili Ostrov, PhD, (Harvard Medical School, HMS) and colleagues advocate for …

Follow Genomics:    

Predictive Oncology Inc.’s (NASDAQ: POAI) Unique Assets, AI Capability Address Unmet Need in Growing Field of Precision Medicine | 11/8/2019

… Medicine as “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person,” the approach is gaining momentum as data sets especially in genomics have grown rapidly. Applying AI approaches to these large data sets offers the ability to more deeply analyze these data much faster and with more accurate results than previously. Predictive Oncology is at the forefront …

$POAI Unique Assets, AI Capability Address Unmet Need in Growing Field of Precision Medicine | 11/8/2019

… Medicine as “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person,” the approach is gaining momentum as data sets especially in genomics have grown rapidly. Applying AI approaches to these large data sets offers the ability to more deeply analyze these data much faster and with more accurate results than previously. Predictive Oncology is at the forefront …

Novogene Adopts Bionano’s Saphyr System Adding Saphyr’s Ultra-Sensitive and Ultra-Specific Structural Variation Detection to their Repertoire of Services | Globe Newswire | 11/7/2019

… of Services Novogene’s global customers will now have a high-throughput solution for long-read genome analysis enabling clinical-grade structural variation discovery and platinum genome assembly 06 nov. 2019 18h03 HE Source : Bionano Genomics SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) – Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Novogene has adopted the Saphyr system for genome imaging and incorporated it into their expansive repertoire of genome analysis technology …

Novogene Adopts Bionano’s Saphyr System Adding Saphyr’s Ultra-Sensitive and Ultra-Specific Structural Variation Detection to their Repertoire of Services | Benzinga | 11/7/2019

… is among the largest and most advanced in the world. With service facilities spanning the globe, and headquarters in Beijing, China, Novogene offers access to cutting edge technologies and bioinformatics expertise to the largest genomics markets in the world. Their customers include academic and industrial scientists and clinicians from the most prestigious universities and pharmaceutical companies around the world. We believe that Novogene’s adoption of Bionano’s Saphyr system for ultra …

Novogene Adopts Bionano’s Saphyr System Adding Saphyr’s Ultra-Sensitive and Ultra-Specific Structural Variation Detection to their Repertoire of Services Nasdaq:BNGO | Globe Newswire | 11/7/2019

… is among the largest and most advanced in the world. With service facilities spanning the globe, and headquarters in Beijing, China, Novogene offers access to cutting edge technologies and bioinformatics expertise to the largest genomics markets in the world. Their customers include academic and industrial scientists and clinicians from the most prestigious universities and pharmaceutical companies around the world. We believe that Novogene’s adoption of Bionano’s Saphyr system for ultra …

Aural Analytics and TGen Announce ALS Research Collaboration | 11/7/2019

Blog This Aural Analytics, Inc. , a privately-held digital health company focused on building the world’s most advanced speech analytics platform, and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope and a non-profit organization dedicated to conducting groundbreaking research with life-changing results, today announced plans to collaborate on research in patients with amyotrophic lateral sclerosis (ALS). The TGen-sponsored clinical trial will assess recently …

Growing New Orleans Biotech Companies To Create Over 275 Jobs | 11/7/2019

… at the University of New Orleans and the New Orleans BioInnovation Center. November 7, 2019 Growing New Orleans Biotech Companies To Create Over 275 Jobs Expansions by three New Orleans biotech firms – AxoSim, Cadex Genomics and Obatala Sciences – will create 135 new direct jobs at the University of New Orleans (UNO) and the New Orleans BioInnovation Center, a biotech incubator where all three companies launched local startup operations. Pictured (l …

Method Finds Patterns in Patients with Multiple Chronic Conditions | HealthIT Analytics | 11/7/2019

… aged 50 and 65 with high blood pressure and high cholesterol were the costliest segment overall. The most surprisingly common disease pair was lung disease and heart attacks. Dig Deeper NIH Clinical Trials Apply Genomics to Chronic Disease Management The study could help inform future work on managing chronic conditions, and highlights several unexpected disease clusters and their costs. Chronic conditions are the leading cause of death and disability in …

Research Fellows in Bioinformatics | Nature | 11/7/2019

… Biology or related areas • 3 years recent relevant work experience to include Programming skills in one of the following languages: Perl, Python, C/C++, SBML , Fortran or Shell scripting • Experience in analysing high throughput genomics datasets such as ChIP-seq and RNA -seq Further information about the Centre and Group can be found at …

ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells | BMJ | 11/7/2019

… for Genetics and Molecular Medicine , University of Louisville , Louisville , Kentucky , USA 5 Dept of Gastroenterology , Hospital Clínic and IDIBAPS , Barcelona , Spain 6 Gastrointestinal and Pancreatic Oncology Team, CIBERehd , Barcelona , Spain 7 Group of Translational Genomics and Targeted Therapeutics in Solid Tumours, Dept of Medical Oncology , Hospital Clínic and IDIBAPS , Barcelona , Spain 8 Dept of Ophthalmology and Visual Sciences and Birth Defects Center , University of Louisville , Louisville , Kentucky , USA 9 Molecular …

Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA: cohort profile | BMJ | 11/7/2019

… system . Available: https://www.cdc.gov/brfss/index.html [Accessed 9 Jan 2019 ]. ↵ Han LC , Olson JE , et al . Potential bias in the bank: what distinguishes refusers, nonresponders and participants in a clinic-based biobank? . Public Health Genomics 2013 ; 16 : 118 – 26 …

Targos and Ultivue Partner to Incorporate Highly Standardized UltiMapper™ Tissue Multiplex Phenotypic Assays in Support of Clinical Research Services | Business Wire | 11/7/2019

Kid Scoop AP Targos and Ultivue Partner to Incorporate Highly Standardized UltiMapper™ Tissue Multiplex Phenotypic Assays in Support of Clinical Research Services Nov 7, 2019 Save KASSEL, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov 7, 2019– Targos Molecular Pathology GmbH, a market leader in clinical biomarker services announced today a technology partnership with Ultivue, the innovation leader in multiplex tissue biomarker assays, to offer the biopharmaceutical industry new capabilities to improve …

GenomOncology’s Precision Oncology Platform to be implemented at Nationally Recognized Academic Medical Center | Markets Insider | Business Insider | 11/7/2019

… pathways, drugs, alterations, transcripts, and diseases. GO’s KMS clinical trial database contains over 4,100 clinical trials curated by the My Cancer Genome team for comprehensive clinical reporting. ABOUT GENOMONCOLOGY GenomOncology enables the application of genomics in oncology to improve patient care. We have applied our expertise in genomics, technology, and data integration to create solutions for cancer care providers. Our solutions are end-to-end: from the data coming out …

BC Platforms Opens New Entity in Singapore to Spearhead its Asia Pacific Strategy and Hosts Launch Event in Precision Medicine | PR Newswire | 11/7/2019

… occasion, BC Platforms is jointly hosting a launch event with the Finnish Government (Business Finland) and IQVIA on 13 th November focusing on Precision Medicine. The event will be attended by leading authorities in genomics including Professor Tai E Shyong, Director, Centre for Precision Health, National University Health System, Singapore , and Dr Kathleen Barnes , Head of Biomedical Informatics and Personalized Medicine in University of Colorado , and takes place at the …

Three Biotech Firms Plan Expansion in New Orleans, Louisiana | 11/7/2019

Three biotech firms, AxoSim, Cadex Genomics and Obatala Sciences, will create 135 new jobs in New Orleans, Louisiana . All three firms have launched local startup operations at the University of New Orleans and New Orleans BioInnovation Center, a biotech incubator. AxoSim’s innovative neuroscience drug discovery platforms are based upon technology licensed from Tulane University. The company will expand its existing facilities at the BioInnovation Center, and AxoSim projects adding 75 …

Lantern Pharma CEO Panna Sharma to Present & Participate in Panel Discussion at AI Applications in Biopharma Summit 2019 in Boston | Globe Newswire | 11/7/2019

… November 11 th , 2019. As part of the panel titled “An AI Powered Project: Human Genetics & Drug Discovery,” Sharma will highlight and discuss AI’s impact within healthcare and drug discovery when applied with human genomics and transcriptome date from drug efficacy studies. The panel discussion will take place on day one of the two-day event, on Monday, November 11, 2019 at 4:00pm ET. Sharma will present key learnings from …

ARK Invest Acknowledges the Five-Year Anniversary of Its Four Original Actively Managed Exchange Traded Funds | PR Newswire | 11/7/2019

… made its full suite of actively managed ETFs available in Canada with its partner Emerge Canada Inc. Listed on the NEO Exchange, the Funds include: Emerge ARK Global Disruptive Innovation ETF (EARK), Emerge ARK Genomics & Biotech ETF (EAGB), Emerge ARK Fintech Innovation ETF (EAFT), Emerge ARK AI & Big Data ETF (EAAI), and the Emerge ARK Autonomous Tech & Robotics ETF (EAUT). About ARK Investment Management LLC Headquartered in New York City …

Global X Publishes Inaugural Thematic ETF Report and Classification System | Globe Newswire | 11/7/2019

The report will publish quarterly, analyzing recent trends among thematic ETFs ~~ 30 ET Source: Global X photo-release New York, NEW YORK – November 07, 2019 – Global X ETFs, the New York-based provider of exchange-traded funds, today published its first Thematic ETF Report , which will be published on a quarterly basis going forward. Global X’s research team will provide industry-level analysis of the number of pertinent funds in …

Precision Medicine

Predictive Oncology Inc.’s (NASDAQ: POAI) Unique Assets, AI Capability Address Unmet Need in Growing Field of Precision Medicine | 11/8/2019

Predictive Oncology is at forefront of growing trend of precision medicine The company applies smart tumor profiling, AI platform to extensive genomic and biomarker patient data sets POAI has large amounts of historical, standardized patient … the approach is gaining momentum as data sets especially in genomics have grown rapidly. Applying AI approaches to these large data sets offers the ability to more deeply analyze these data much faster and with …

$POAI Unique Assets, AI Capability Address Unmet Need in Growing Field of Precision Medicine | 11/8/2019

November 7, 2019 Predictive Oncology is at forefront of growing trend of precision medicine The company applies smart tumor profiling, AI platform to extensive genomic and biomarker patient data sets POAI has large amounts of … the approach is gaining momentum as data sets especially in genomics have grown rapidly. Applying AI approaches to these large data sets offers the ability to more deeply analyze these data much faster and with …

Biotech

Predictive Oncology Inc.’s (NASDAQ: POAI) Unique Assets, AI Capability Address Unmet Need in Growing Field of Precision Medicine | 11/8/2019

… individual variability in genes, environment, and lifestyle for each person,” the approach is gaining momentum as data sets especially in genomics have grown rapidly. Applying AI approaches to these large data sets offers the ability … of artificial intelligence and work with the pharmaceutical, diagnostic, and biotech industries to develop AI-driven predictive models of tumor drug response to impact patient outcomes. For more information, visit the company’s website at www.Predictive …

$POAI Unique Assets, AI Capability Address Unmet Need in Growing Field of Precision Medicine | 11/8/2019

… individual variability in genes, environment, and lifestyle for each person,” the approach is gaining momentum as data sets especially in genomics have grown rapidly. Applying AI approaches to these large data sets offers the ability … of artificial intelligence and work with the pharmaceutical, diagnostic, and biotech industries to develop AI-driven predictive models of tumor drug response to impact patient outcomes. For more information, visit the company’s website at www.Predictive …

Big Pharma

Predictive Oncology Inc.’s (NASDAQ: POAI) Unique Assets, AI Capability Address Unmet Need in Growing Field of Precision Medicine | 11/8/2019

… individual variability in genes, environment, and lifestyle for each person,” the approach is gaining momentum as data sets especially in genomics have grown rapidly. Applying AI approaches to these large data sets offers the ability … recent overview ( http://ibn.fm/pYVQI ), POAI notes that for years, big pharma has invested tremendous resources — both financial and human — in genomics in order to understand a patient’s genome and hopefully provide more targeted treatments …

$POAI Unique Assets, AI Capability Address Unmet Need in Growing Field of Precision Medicine | 11/8/2019

… individual variability in genes, environment, and lifestyle for each person,” the approach is gaining momentum as data sets especially in genomics have grown rapidly. Applying AI approaches to these large data sets offers the ability … recent overview ( http://nnw.fm/w8W7b ), POAI notes that for years, big pharma has invested tremendous resources — both financial and human — in genomics in order to understand a patient’s genome and hopefully provide more targeted treatments …

Medical Research

Researcher (Postdoc) Unravelling the agonistic potential of MuSK Monoclonal Antibodies | Nature | 11/7/2019

… head of the department) and Neurology (Prof. Dr. Jan Verschuuren, head of the department). Both departments have a longstanding collaboration on research of Neurological Motor Disorders. This research is embedded in the LUMC Medical Research Profile ‘Translational Neurosciences’. The collaboration facilitates translational research based on fundamental research, patient material and clinical expertise. It is also supported through interactions with other departments both within and outside the LUMC . The Neuroimmunology research …

BC Platforms Opens New Entity in Singapore to Spearhead its Asia Pacific Strategy and Hosts Launch Event in Precision Medicine | PR Newswire | 11/7/2019

… Finland) and IQVIA on 13 th November focusing on Precision Medicine. The event will be attended by leading authorities in genomics including Professor Tai E Shyong, Director, Centre for Precision Health, National University Health System … to provide genomic and clinical cohort data for pharmaceutical and medical research and development. BC Platforms’ vision is to build the world’s leading analytics platform for healthcare and industry by 2020, providing access to diverse …

NIH

Method Finds Patterns in Patients with Multiple Chronic Conditions | HealthIT Analytics | 11/7/2019

NIH Clinical Trials Apply Genomics to Chronic Disease Management The study could help inform future work on managing chronic conditions, and highlights several unexpected disease clusters and their costs. Chronic conditions are the leading cause of death and disability in the US, Mount Sinai researchers noted, and it has become increasingly common for adults in the US to live with more than one. To uncover patterns among patients with multiple …

Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma | Nature | 11/7/2019

… research design is available in the Nature Research Reporting Summary linked to this article. Data availability Targeted deep sequencing and RNA-sequencing data have been submitted to NCBI Sequence Read Archive (SRA) ( https://www.ncbi.nlm.nih.gov/sra/ ) with the accession number PRJNA431487. The source data underlying Figs. 3 b, 3 d, 4 a, 4 b, 5 a, 5 c, 6c and Supplementary Fig. 1 a, 1 b, 5 b, 5 c, 5 …

Clinical Research

Novogene Adopts Bionano’s Saphyr System Adding Saphyr’s Ultra-Sensitive and Ultra-Specific Structural Variation Detection to their Repertoire of Services | Globe Newswire | 11/7/2019

… read genome analysis enabling clinical-grade structural variation discovery and platinum genome assembly 06 nov. 2019 18h03 HE Source : Bionano Genomics SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) – Bionano Genomics, Inc. (Nasdaq: BNGO) announced today … to, basic human research, translational research for variant discovery and clinical research in cancer and genetic diseases. In addition, data generated with the Saphyr system can be integrated with the extensive array of Novogene’s offerings …

Novogene Adopts Bionano’s Saphyr System Adding Saphyr’s Ultra-Sensitive and Ultra-Specific Structural Variation Detection to their Repertoire of Services | Benzinga | 11/7/2019

SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) – Bionano Genomics, Inc. (NASDAQ: BNGO ) announced today that Novogene has adopted the Saphyr system for genome imaging and incorporated it into their expansive repertoire of genome analysis technology … to, basic human research, translational research for variant discovery and clinical research in cancer and genetic diseases. In addition, data generated with the Saphyr system can be integrated with the extensive array of Novogene’s offerings …

CRISPR

Science X Newsletter Wednesday, Nov 6 | 11/7/2019

… high-risk variant was common in African populations (around 20%), but essentially absent in all other ancestral groups. Doctors try CRISPR gene editing for cancer, a 1st in the US The first attempt in the … Pujol Research Institute (IGTP), where he leads the Endocrine Regulatory Genomics group. Mireia Ramos-Rodríguez, the first author of the paper, is a doctoral student in the Endocrine Regulatory Genomics group. The study was carried …

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/7/2019

… transfusion dependent with disease that is severe enough to have required at least eight packed red blood cell transfusions for each of the two prior years. It’s notable that a competitive study using CRISPR/Cas9 editing technology allows enrollment of significantly less severe patients with potentially as few as four transfusion events per year for a typical adult patient. The ASH Abstract posted this morning shows that the first three …

Medicare

DermTech, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update | The Wapakoneta Daily News | 11/7/2019

DermTech, Inc. ( NASDAQ: DMTK ) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported business and financial results as of and for the quarter ended September … force, and establishing our reimbursement code and anticipated price with Medicare. We are off to a strong start as a newly public company and I look forward to a successful year,” said John Dobak, M.D …

Natera Reports Third Quarter 2019 Financial Results | PR Newswire | 11/6/2019

Medicare for reimbursement of Signatera™ in colorectal cancer. Completed key technical and commercialization milestones with BGI Genomics. Entered into partnership to develop and commercialize personalized circulating tumor DNA monitoring assays with Foundation Medicine. Successfully completed $230 million follow-on equity offering. “Q3 was in many ways a transformational quarter for Natera,” said Steve Chapman , Natera’s CEO. “We continued to see strong momentum in volume growth and improved average selling price …

Clinical Diagnostics

Prevalence and Genetic Identification of Three Entamoeba Species in Pigs in Southeastern China | 11/7/2019

Research Article Prevalence and Genetic Identification of Three Entamoeba Species in Pigs in Southeastern China Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, China Correspondence should be addressed to Dong-Hui Zhou ; Received 1 August 2019; Revised 3 October 2019; Accepted 15 October 2019; Published 7 November 2019 Academic Editor: Stefano D’Amelio Copyright © 2019 …

DermTech, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update | The Wapakoneta Daily News | 11/7/2019

DermTech, Inc. ( NASDAQ: DMTK ) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported business and financial results as of and for the quarter ended September 30, 2019 and provided a corporate update. Third Quarter 2019 Business Highlights: Received Proprietary Laboratory Analyses (“PLA”) code (0089U) and favorable crosswalk recommendation to code 0005U by Clinical Diagnostic Laboratory Test Committee (“CDLT”) Signed new …

Food and Drug Administration

Science X Newsletter Wednesday, Nov 6 | 11/7/2019

… could affect results of medical tests Biotin supplements can interfere with the results of some critical lab tests, the U.S. Food and Drug Administration warned Tuesday. How to head off holiday weight gain From Halloween … Pujol Research Institute (IGTP), where he leads the Endocrine Regulatory Genomics group. Mireia Ramos-Rodríguez, the first author of the paper, is a doctoral student in the Endocrine Regulatory Genomics group. The study was carried …

Global Nanotechnology and Nanomedicine Treatment Markets Could Reach $350 Billion by 2025 | PR Newswire | 11/7/2019

… these developments in more detail during our call and at our R&D day on November 15 th .” GlaxoSmithKline plc (NYSE: GSK ) recently announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer patients, who have …

Thermo Fisher

CRISPR and CRISPR-Associated (Cas) Genes Market Report by Merck KGaA,Addgene,CRISPR THERAPEUTICS,Thermo Fisher Scientific, Inc.,Mirus Bio LLC, etc | by 2027 | 11/7/2019

Press Releases CRISPR and CRISPR-Associated (Cas) Genes Market Report by Merck KGaA,Addgene,CRISPR THERAPEUTICS,Thermo Fisher Scientific, Inc.,Mirus Bio LLC, etc by 2027 The Insight Partners’ report on the CRISPR and CRISPR … the market is segmented into genome engineering, disease models, functional genomics, knockdown/activation and others. Based on end user the market is segmented into biotechnology and pharmaceutical companies, academic and government research institutes, contract research …

Oligonucleotides Synthesis Market studies 2019 with top Companies profile like Agilent Technologies, Inc., Atdbio Ltd., LGC Limited, Bio-Synthesis Inc. | 11/7/2019

… and strategies. Key players profiled in this report are: Agilent Technologies, Inc., Atdbio Ltd., LGC Limited, Bio-Synthesis Inc., Eurofins Genomics, Kaneka Eurogentec S.A., General Electric, Genscript, AJINOMOTO CO.,INC (Genedesign, Inc.), Danaher Global oligonucleotides … Genedesign, Inc.), Danaher, Merck Kgaa, Lgc Biosearch Technologies, Nitto Denko, Thermo Fisher Scientific, Trilink Biotechnologies, Llc, Biolytic Lab Performance Inc., Polygen Gmbh, Quintara Biosciences, Bio Basic Inc., Danaher (Integrated Dna Technologies, Inc.), and Twist Bioscience …

Merck

Pfenex Reports Third Quarter 2019 Results and Provides Business Update | Globe Newswire | 11/7/2019

… CRM197 is currently being used by Pfenex’s vaccine development focused pharmaceutical partners, including in multiple Phase 3 clinical studies by Merck and the Serum Institute of India Private Ltd. (SIIPL) for such diseases as pneumococcal … one of the world’s top experts on the genetics and genomics of circadian rhythms. Having published more than 200 papers, he was named by Thomson Reuters as one of “The World’s Most Influential Scientific Minds …

Reuters Health News Summary | Yahoo News | 11/7/2019

… Johnson said on Thursday it had filed for an approval from European regulators for its two-dose experimental vaccine to protect against Ebola, less than a month after the agency recommended approval of Merck & Co Inc’s vaccine. J&J said it submitted two marketing authorization applications to the European Medicines Agency (EMA) for its vaccine regimen targeting the Zaire strain of the Ebola virus, which most commonly causes outbreaks of …

Celgene

Global Nanotechnology and Nanomedicine Treatment Markets Could Reach $350 Billion by 2025 | PR Newswire | 11/7/2019

… that’s why we’re working there.” Active biotech and big pharma stocks in the market today include: Constellation Pharmaceuticals, Inc . (NASDAQ: CNST ), NanoViricides, Inc. (NYSE: NNVC ), Agenus Inc. (NASDAQ: AGEN ), GlaxoSmithKline plc (NYSE: GSK ), Celgene Corporation (NASDAQ: CELG ). According to Grand View Research, the global nanomedicine market is anticipated to reach USD 350.8 billion by 2025. The report continued: “Development of novel nanotechnology-based drugs and therapies is driven by the …

Theranostics Market Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to 2026 | 11/6/2019

… a robust prototype immunohistochemistry assay as a future companion diagnostic test for W0101 (the drug candidate which they are developing together) and extended this collaboration in May 2018. Abbott Laboratories, Inc. collaborated with Celgene Corporation, and Agios Pharmaceuticals, to develop diagnostic tests on Abbott’s m2000 RealTime system that identifies certain genomic mutations associated with acute myeloid leukemia (AML) in 2016. These factors are expected to support global theranostics market growth …

Qiagen

Complementary Embryonic and Adult Cell Populations Enhance Myocardial Repair in Rat Myocardial Injury Model | 11/3/2019

… FL 32611, USA 4 Department of Pharmacodynamics, University of Florida, Gainesville, FL 32611, USA 5 Department of Physiology and Functional Genomics, University of Florida, Gainesville, FL 32611, USA 6 Department of Biostatistics, University of Texas … Chain Reaction Cell extract total mRNA was isolated (RNeasy kit; Qiagen Inc.) as per the manufacturer’s instructions. The mRNA was then transcribed (iScript™ cDNA Synthesis Kit; Bio-Rad, Hercules, CA), and real-time PCR was …

Modified Huang-Lian-Jie-Du Decoction Ameliorates Aβ Synaptotoxicity in a Murine Model of Alzheimer’s Disease | 11/3/2019

… on dry ice, and stored at −80°C. The 16S rDNA analysis of the fecal samples was performed by Anjie Medical Co., Ltd. (Xiamen, China). DNA extraction was performed using PowerFecal DNA kits (QIAGEN, Duesseldorf, Germany). Genomic DNA was amplified in 50 μ l triplicate reactions with bacterial 16S rDNA gene (V3–V4 regions)-specific primers: 341F (5 - CCTAYGGGRBGCASCAG-3 ) and 806R (5 - GGACTACNNGGGTATCTAAT-3 ). The reverse primer contained a …

GSK

Remote Ischemic Preconditioning Protects Cisplatin-Induced Acute Kidney Injury through the PTEN/AKT Signaling Pathway | 11/3/2019

… as the previous description [ 13 ]. The primary antibodies anti-PTEN, anti-p-PTEN, anti-p-AKT, anti-AKT, anti-p-GSK3 β , anti-GSK3 β , anti-BAX, and anti-BCL-2 were purchased from Cell … at Google Scholar · View at Scopus D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell , vol. 116, no. 2, pp. 281–297, 2004. View at Publisher · View at Google Scholar · View at Scopus L …

European Project Launches to Tailor Autoimmune Disease Treatments | 10/31/2019

… to know how well a treatment will work in each individual patient. The 3TR project will use techniques such as genomics and transcriptomics to tackle this problem, and help healthcare providers to prescribe the most … partners in the project include big pharma companies such as GSK and AstraZeneca, charities such as the European Lung Foundation, and academic institutions such as the Swedish Karolinska Institutet. The partners will outline their plans …

Quest Diagnostics

WRL for Nov 2 | 11/2/2019

… 4.07 ▲ 7 7.29% Discover Financial Services DFS 81.72 81.84 -1.12 ▲ 4 -5.38% Dollar General DG 159.90 146.28 8.36 ▼ 42 38.06% Quest Diagnostics DGX 101.59 98.57 1.18 ▼ 27 6.58% DR Horton Inc DHI 53.30 47.49 6.47 … 7 5.30% Noble Corp NE 1.33 1.90 -2.39 ▼ 53 73.51% NeoGenomics Inc NEO 22.68 22.88 -3.77 ▲ 7 -6.66% Neogen Corp NEOG 65.22 69.19 -1.56 ▼ 5 -0.24% New Media Investment NEWM 8.48 9.81 -1.85 ▲ 12 -4.82 …

OTC/DTC Infectious Disease Diagnostics to 2024: Global Industry Overview, Market Size & Trends, Recent Developments, Profiles of Key Players | 11/1/2019

… Genomics. GenePOC Diagnostics GenMark Dx Healthy.IO Hologic Inflammatix Inui Health Invetech Janssen Diagnostics Karius Labcorp – Pixel Letsgetchecked Lexigene Luminex Mbio Diagnostics Mesa Biotech Mobidiag myLabBox Mylan Nanomix Orasure Oxford Nanopore Panagene Primerdesign Prominex Qiagen (Statdx) Quantumdx Quest Diagnostics – Quest Direct Roche Molecular Diagnostics Scanwell Health Seegene Sensovation Seventh Sense Biosystems Siemens Healthineers (Fast Track Diagnostics) SkylineDx T2 Biosystems TestCard Diagnostics Thermo Fisher Thriva Veramarx XCR Diagnostics 7. Global Market Size …

Biogen

WRL for Nov 2 | 11/2/2019

… 4.21 ▼ 13 16.61% Broadcom Ltd AVGO 296.59 275.64 0.52 ▲ 0 0.00% Buy Baidu Inc BIDU 104.64 117.05 -1.77 ▲ 65 55.30% Biogen Inc BIIB 299.20 234.37 2.82 ▲ 1 5.44% Booking Holdings BKNG 2032.02 1933.45 2.52 ▲ 19 … 7 5.30% Noble Corp NE 1.33 1.90 -2.39 ▼ 53 73.51% NeoGenomics Inc NEO 22.68 22.88 -3.77 ▲ 7 -6.66% Neogen Corp NEOG 65.22 69.19 -1.56 ▼ 5 -0.24% New Media Investment NEWM 8.48 9.81 -1.85 ▲ 12 -4.82 …

Global Whole Genome And Exome Sequencing Market Report 2019: Forecast to 2023 & Executive and Consultant Guides 2020 to 2024 | Markets Insider | Business Insider | 11/1/2019

… 1.1.1 Whole and Exome Sequencing 1.1.2 Research and Clinical 1.1.3 Direct to Consumer 1.1.4 AgriBio 1.1.5 Tumor Cells 1.2 The Genomics Revolution 1.3 Market Definition 1.3.1 Revenue Market Size 1.4 U.S. Medical Market and laboratory … Mayo Collaboration with Veritas Regeneron Partners With AbbVie, Alnylam, AstraZeneca, Biogen, Pfizer to Sequence UK Biobank Samples MedGenome Expands Its NGS Capabilities and Forays Into Single-Cell Sequencing Genomics England Adopts Edico’s Dragen For NGS …

GlaxoSmithKline

Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer | 11/1/2019

… ownership interest in a patent related to BH3 profiling. J. Ryan is a consultant for Vivid Bioscience, has ownership interest (including patents) in Dana-Farber Cancer Institute. J.L. Guerriero is a consultant for GlaxoSmithKline and reports receiving a commercial research grant from the same. J. Montero is a consultant for Oncoheroes Biosciences and Vivid Biosciences. A.D. Cherniack reports receiving other commercial research support from Bayer AG. A. Letai is a …

Influenza Vaccines Market Share, Revenue, Demand and Forecast to 2025 | 10/31/2019

… agreement to acquire the influenza vaccines business of Novartis for US$275 million. Ø Furthermore, in July 2017, Sanofi bought the vaccine biotech Protein Sciences for $750 million. Ø Moreover, in October 2019, GlaxoSmithKline Biologicals got approval for their influenza virus vaccine “Fluarix Quadrivalent” by the FDA. Ø Additionally, in October 2019, Seqirus Pty. Ltd. got FDA’s approval for their influenza virus vaccine “Afluria Quadrivalent”. Key player’s profiles in the …

Boehringer Ingelheim

Loss of ZnT8 function protects against diabetes by enhanced insulin secretion | Nature | 11/1/2019

… on advisory panels for Pfizer, Novo Nordisk, Zoe Global; has received honoraria from Pfizer, Novo Nordisk and Eli Lilly; has stock options in Zoe Global; has received research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Servier, Takeda. G.A.R. is a consultant for Sun Pharma and has received grant funding from Servier. J.O.L. has received research funding from Pfizer Inc. and …

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,[email protected], Telephone consultation 11855 int 1193, | 10/30/2019

… Asian Patients With Different Types of Advanced Cancer (Solid Tumours)Condition: Neoplasm Interventions: Drug: BI 891065; Drug: BI 754091 Sponsor: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Cancer & Oncology Clinical TrialsFri Oct 25, 2019 … Oct 29, 2019 16:24 ScienceDirect Publication: Journal of Genetics and Genomics, Acquisition of functional neurons… ScienceDirect Publication: Journal of Genetics and Genomics,Acquisition of functional neurons by direct conversion: Switching the developmental clock directlyPublication date …

AdventHealth

Genetic Testing Markets, World Outlook to 2024 - Fertility Practice Growth Drives the Market, Pharmacogenomics Drives Further Growth | Globe Newswire | 11/1/2019

… Key Genetics Players - Analysis 3. Market Trends 3.1.1 Genetic Discoveries Creating New Diagnostic Markets3.1.2 Aging Population a Boon for Diagnostics3.1.3 Pharmacogenomics Drives Further Growth3.1.4 Oncology and Liquid Biopsy Enter New Era3.1.5 Fertility Practice Growth drives … Embark Veterinary Raises $10M Yourgene Health to Acquire Elucigene Helix, AdventHealth Partner on Genetic Screening Study Qiagen, NeuMoDx Ink Partnership, Merger Agreement Prenetics Acquires DNAFit for $10M Myriad Genetics to Acquire Counsyl for $375M Roche …

Genetic Testing Markets, World Outlook to 2024 – Fertility Practice Growth Drives the Market, Pharmacogenomics Drives Further Growth | 11/1/2019

… format on request Key Topics Covered 1. Introduction and Market Definition 1.1 Genetic Testing Definition in This Report 1.2 The Genomics Revolution 1.3 Market Definition 1.3.1 Revenue Market Size 1.4 U.S. Medical Market and laboratory … Embark Veterinary Raises $10M Yourgene Health to Acquire Elucigene Helix, AdventHealth Partner on Genetic Screening Study Qiagen, NeuMoDx Ink Partnership, Merger Agreement Prenetics Acquires DNAFit for $10M Myriad Genetics to Acquire Counsyl for $375M Roche …

Illumina Ventures

Principal/Senior Scientist, Protein Chemistry - Analytical Development - San Francisco, CA, , USA #jobs #San Francisco pls RT | 10/23/2019

… Illumina Ventures, and Matrix Capital Management. For more information, please visit www.Encoded.com.This is a unique opportunity to work at the intersection of genomics and therapeutics and participate in the development of a diverse therapeutic pipeline driven by a transformative core technology. The position of Principal/Senior Scientist, Protein Chemistry is part of the Analytical Development team and will lead the development and optimization of analytical methods using biophysical/biochemical technology …

Andreessen Horowitz

SynBioTech showed the real future of Silicon Valley: biology | CNBC | 10/4/2019

… chemical-based processes, and its organizer John Cumbers previously worked as a synthetic biologist at NASA. VIDEO 3:03 03:03 Geneticist: Genomics will become a core part of medicine The Edge The event was a refreshing … culture vibe to it,” said Jorge Conde, an investor at Andreessen Horowitz, who spoke at the event. Conde said that the founders are a “new breed” and they reminded him of the first generation of …

Invitae to Acquire Jungla to Advance Genetic Variant Interpretation, Adds Supplemental RNA Analysis to Deliver Deeper, More Informative Results to Patients | PR Newswire | 7/12/2019

SAN FRANCISCO , July 11, 2019 /PRNewswire/ – Invitae Corporation (NYSE: NVTA ), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Jungla Inc. , a privately held company funded by Andreessen Horowitz (a16z) that has developed a cloud-based platform that combines clinical knowledge with advances in functional genomics, biophysics, cellular engineering, machine learning, and distributed systems to help clinicians and patients understand the results of …

Harvard Medical School

A Roadmap and Wish List for Synthetic Genomics | 11/8/2019

… genomics, where instead of one protein or gene, entire genomes are designed, synthesized, and implemented. To make synthetic genomics bloom, it needs new innovations and support, concludes a new report by a consortium of scientists from academia and industry, published recently in Science . Nili Ostrov, PhD, (Harvard Medical School, HMS) and colleagues advocate for advances in four areas they believe are critical for making synthetic genomics as much a part …

George Church | 11/7/2019

… united States]] Latest revision as of 19:37, 7 November 2019 “Dr. George Church is the founding core faculty member and platform lead for synthetic biology at the Wyss Institute ; professor of genetics at Harvard Medical School; and professor of health sciences and technology at Harvard and MIT. As the lead scientist of the Wyss Institute’s synthetic biology platform, George oversees the directed evolution of molecules, polymers, and whole genomes to …

Massachusetts General Hospital

Four extra hours of weekly exercise will reduce your depression significantly | 11/7/2019

… to a study that may lead to better clinical strategies to counter the mental disorder. The researchers, including those from Massachusetts General Hospital in the US, said people may see a 17 per cent reduction … research shows the value of real-world healthcare data and genomics to provide answers that can help us to reduce the burden of these diseases,” said Jordan Smoller senior author of the study from Harvard …

Physical exercise could profoundly reduce the risk of depressive episodes - Mental Daily | 11/7/2019

More Photo via: morningsidenews.co.za For depressive episodes, increasing the amount of physical exercise to several hours a week, at a minimum, could profoundly reduce the risk of depression, new research suggests. As part of a study conducted at Massachusetts General Hospital in Boston, Massachusetts, researchers racked the genomic and health data of an estimated 8,000 participants from the Partners Healthcare Biobank. The main objective of the study, as published in …

Intermountain Healthcare

(USA-UT-Provo) Population Genomics Research Assistant- Various Locations | 11/2/2019

… role. Prior experience working with laboratory protocol, systems and documentation techniques. 1 year clinical research experience Associate Degree or higher Prior experience in healthcare Please Note All positions subject to close without notice. Intermountain Healthcare prohibits discrimination on the basis of race, ethnicity, religion, color, national origin, sex, age, sexual orientation, gender identity/expression, veteran status, disability and/or genetic information. Additional Details: Working Hours 40 Primary Work Location Riverton …

How RxMatch Helped a Patient Finally Get the Right Blood Pressure Medication | 11/1/2019

… Right Blood Pressure Medication Salt Lake City, UT – ( ReleaseWire ) – 11/01/2019 –Joan Eggert, MD, has become an advocate for Intermountain Precision Genomics’ RxMatch — which uses a simple cheek swab to help determine the most appropriate treatment … story here . To learn more about RxMatch, visit Intermountain.com/RxMatch . Intermountain Healthcare is a not-for-profit system of 24 hospitals, 215 clinics, a Medical Group with 2,500 employed physicians and advanced practice clinicians, a …

Ochsner Health System

11 recent vendor contracts, go lives | Becker’s Hospital Review | 10/25/2019

Ochsner Health System announced a pilot program in partnership with genomics company Color to integrate genomic insights into standard clinical care. 4. Jackson-based University of Mississippi Medical Center announced Oct. 21 that it has released a new mobile health app from C Spire Health designed to treat patients with non-emergency conditions. 5. Houston Methodist has formed an “innovation relationship” with Notable Health to connect the patient experience and …

Ochsner Health System, Color team on population health pilot program | 10/21/2019

Ochsner Health System and genetic testing vendor Color are collaborating on what they contend is a “first of its kind, fully digital” population health pilot integrating clinical genomics into standard care. “The partnership leverages Color’s unique combination of medical grade genetics, clinical services and patient engagement with Louisiana-based Ochsner’s approach to making individualized patient-level insights actionable and integrating them into routine patient care at scale,” according to the …

George Church

George Church | 11/7/2019

Difference between revisions of “George Church” From SourceWatch [[category:united States]] Latest revision as of 19:37, 7 November 2019 “Dr. George Church is the founding core faculty member and platform lead for synthetic biology at the Wyss Institute ; professor of genetics at Harvard Medical School; and professor of health sciences and technology at Harvard and MIT. As the lead scientist of the Wyss Institute’s synthetic biology platform, George oversees the …

Hans Cobben

Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution | PR Newswire | 10/15/2019

… of accelerating precision medicine, which we are thrilled to make tangible for a global market,” Dr. Kim adds. Leveraging BlueBee’s Genomics Platform, Celemics is able to serve an expanding global market with clinical-grade data … data and analyses. “We are honored to serve Celemics,” says Hans Cobben , CEO of BlueBee. “The BlueBee Genomics Platform, configured for the Celemics data workflow, will streamline data analysis through insight generation for target enrichment …

Lexogen partners with BlueBee to automate data analysis for CORALL RNA-Seq kit | PR Newswire | 10/14/2019

Lexogen is a transcriptomics and next generation sequencing company (PRNewsFoto/Lexogen) Genomics data analysis solutions. (PRNewsfoto/Lexogen) VIENNA and RIJSWIJK, Netherlands , Oct. 14, Lexogen and BlueBee, global experts in transcriptome sequencing and bioinformatics, respectively, have … global reach of Lexogen’s portfolio and improves user experience,” said Hans Cobben , Chief Executive Officer at BlueBee. “It is our aim to serve as an extension of our partner-clients, on the solutions front, providing …

Tej Kohli

Tej Kohli Foundation advocates a scalable, accessible and affordable technology solution to end corneal blindness worldwide. | Business Wire | 10/10/2019

LONDON- On World Sight Day, the Tej Kohli Foundation says that a focus on new technologies is needed to accelerate the global mission to end curable corneal blindness worldwide. The Foundation is currently funding the … advanced by exponential growth technologies such as AI, robotics and genomics. The Foundation behaves like a venture fund by backing, incubating, acquiring and accelerating the development of technology solutions. Only successful projects secure further funding …

Jackie Drees

Amazon’s 5 latest health-related job openings | Becker’s Hospital Review | 10/10/2019

Jackie Drees - Amazon recently posted several job openings related to its health business. Five open positions: 1. Senior specialist solutions architect, healthcare informatics and analytics: Will provide technical design and thought leadership to the nonprofit healthcare markets for cloud computing. 2. Senior solutions architect, Amazon Web Services: Will oversee technical engagement and success around specific implementation projects for the nonprofit healthcare markets for cloud computing. 3. Application architect, genomics: Will …

OSF HealthCare integrates genomics software with Epic EHR | Becker’s Hospital Review | 9/19/2019

OSF HealthCare integrates genomics software with Epic EHR Jackie Drees - Print Email Peoria, Ill.-based OSF HealthCare added CancerIQ’s genetic screening software to its Epic EHR as part of its population health initiative to better identify and treat cancer. OSF’s innovation team partnered with CancerIQ in 2015 and implemented the software platform in specialty clinics, including oncology, breast imaging and women’s health. The software, now integrated with Epic, will be …

John Powers

Murrieta Genomics Participating in Silicon Valley Pitch Event | PRWeb | 10/2/2019

Murrieta Genomics , the launch pad for genomic sequencing startups, will be presenting its business opportunity to investors and venture capital companies in Silicon Valley at a special Life Science showcase event on October 10th, 2019 … in the industry to simplify the sample preparation process,” said John Powers, CEO of SimpliSeq. “Our proprietary process eliminates many of the steps currently required to prepare samples for next generation sequencing. This can greatly …

Murrieta Genomics Participating in Silicon Valley Pitch Event | The Wapakoneta Daily News | 10/2/2019

MURRIETA, Calif. , Oct. 2, 2019 /PRNewswire-PRWeb/ – Murrieta Genomics , the launch pad for genomic sequencing startups, will be presenting its business opportunity to investors and venture capital companies in Silicon Valley at a special Life … in the industry to simplify the sample preparation process,” said John Powers , CEO of SimpliSeq. “Our proprietary process eliminates many of the steps currently required to prepare samples for next generation sequencing. This can greatly …

Carl Peck

Former FDA Associate Director for Genomics, Felix Frueh, PhD, Joins NDA Partners as Expert Consultant | Markets Insider | Business Insider | 9/4/2019

ROCHELLE, Va. , Sept. 4, 2019 /PRNewswire-PRWeb/ – NDA Partners Chairman Carl Peck , MD, announced today that Felix Frueh , PhD, a senior life sciences executive with expertise in corporate, regulatory, and commercialization strategies with a focus on precision medicine, who formerly served as the Associate Director for Genomics in the Center for Drug Evaluation and Research, has joined the firm as an Expert Consultant. In his role as Associate Director for …

Raphael Mechoulam

Medicinal Genomics Announces Raphael Mechoulam, the Father of Cannabis Research, Will Headline CannMed 2019, September 23-24, in Pasadena, CA | PR Newswire | 8/20/2019

Professor Mechoulam, who co-created CannMed, will keynote its fourth annual gathering along with more than 50 of the greatest minds in cannabis BEVERLY, Mass. , Aug. 20, Medicinal Genomics Corp. (MGC), a pioneer in genomics and blockchain technology to improve the yield, safety and transparency of cannabis, today announced that Raphael Mechoulam will headline the list of more than 50 speakers and presenters at CannMed 2019 , to be held September …

Medicinal Genomics Announces Raphael Mechoulam, the Father of Cannabis Research, Will Headline CannMed 2019, September 23-24, in Pasadena, CA | BioSpace | 8/20/2019

BEVERLY, Mass. Medicinal Genomics Corp. (MGC), a pioneer in genomics and blockchain technology to improve the yield, safety and transparency of cannabis, today announced that Raphael Mechoulam will headline the list of more than 50 speakers and presenters at CannMed 2019 , to be held September 23-24 at the Pasadena Convention Center, Pasadena CA. CannMed is presented by Medicinal Genomics in partnership with EPM. Professor Mechoulam, EPM Head of Research, will …

Sean George

Invitae to Acquire Jungla to Advance Genetic Variant Interpretation, Adds Supplemental RNA Analysis to Deliver Deeper, More Informative Results to Patients | PR Newswire | 7/12/2019

… funded by Andreessen Horowitz (a16z) that has developed a cloud-based platform that combines clinical knowledge with advances in functional genomics, biophysics, cellular engineering, machine learning, and distributed systems to help clinicians and patients understand … provide support to our patients in a scalable way,” said Sean George , co-founder and chief executive officer of Invitae. “Whether incorporating computational and experimental approaches for protein analysis or adding RNA analysis to augment …

Invitae to Acquire Jungla to Advance Genetic Variant Interpretation, Adds Supplemental RNA Analysis to Deliver Deeper, More Informative Results to Patients | Business & Finance | heraldchronicle.com | PR Newswire | 7/11/2019

… funded by Andreessen Horowitz (a16z) that has developed a cloud-based platform that combines clinical knowledge with advances in functional genomics, biophysics, cellular engineering, machine learning, and distributed systems to help clinicians and patients understand … provide support to our patients in a scalable way,” said Sean George, co-founder and chief executive officer of Invitae. “Whether incorporating computational and experimental approaches for protein analysis or adding RNA analysis to augment …

Hua Chien Chen

ACT Genomics Opens Third Laboratory in Asia at Hong Kong Science Park | Business Wire | 7/5/2019

HONG KONG–(BUSINESS WIRE)–Jul 5, 2019– ACT Genomics Holdings Co., Ltd (“ ACT Genomics ” or the “ Group ”), a leading cancer precision treatment solution provider, yesterday opened its third Next Generation Sequencing (“NGS”) laboratory in Asia … Kong Science and Technology Parks Corporation (“ HKSTP ”); together with Dr Hua Chien CHEN, Chief Executive Officer, Dr Shu Jen CHEN, Chief Scientific Officer, and Mr Victor CHAN, Chief Financial Officer of ACT Genomics. This press …

Victor Chan

ACT Genomics Opens Third Laboratory in Asia at Hong Kong Science Park | Business Wire | 7/5/2019

HONG KONG–(BUSINESS WIRE)–Jul 5, 2019– ACT Genomics Holdings Co., Ltd (“ ACT Genomics ” or the “ Group ”), a leading cancer precision treatment solution provider, yesterday opened its third Next Generation Sequencing (“NGS”) laboratory in Asia … Officer, Dr Shu Jen CHEN, Chief Scientific Officer, and Mr Victor CHAN, Chief Financial Officer of ACT Genomics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190704005351/en/ Dr …